MXPA05005202A - Vacuna. - Google Patents

Vacuna.

Info

Publication number
MXPA05005202A
MXPA05005202A MXPA05005202A MXPA05005202A MXPA05005202A MX PA05005202 A MXPA05005202 A MX PA05005202A MX PA05005202 A MXPA05005202 A MX PA05005202A MX PA05005202 A MXPA05005202 A MX PA05005202A MX PA05005202 A MXPA05005202 A MX PA05005202A
Authority
MX
Mexico
Prior art keywords
hcv
protein
expression
polynucleotide sequence
core protein
Prior art date
Application number
MXPA05005202A
Other languages
English (en)
Inventor
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA05005202A publication Critical patent/MXPA05005202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a metodos y composiciones utiles en el tratamiento y prevencion de las infecciones por el virus de Hepatitis C (VHC) y los sintomas y enfermedades asociadas con el mismo. En particular la presente invencion se refiere a vacunas de ADN que codifican la proteina del nucleo del VHC y una secuencia de polinucleotidos que codifica por lo menos otra proteina VHC, en donde la vacuna ocasiona la expresion de las proteinas dentro de la misma celula y la secuencia de polinucleotidos, secuencia que codifica la proteina nucleo, ha sido mutada o colocada en relacion con secuencia de polinucleotidos que codifican por lo menos la otra proteina de VHC, de modo que es reducido el efecto negativo de la expresion de la proteina del nucleo en la expresion de dicha por lo menos otra proteina de VHC.
MXPA05005202A 2002-11-15 2003-11-13 Vacuna. MXPA05005202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine

Publications (1)

Publication Number Publication Date
MXPA05005202A true MXPA05005202A (es) 2006-01-27

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05005202A MXPA05005202A (es) 2002-11-15 2003-11-13 Vacuna.
MXPA05005203A MXPA05005203A (es) 2002-11-15 2003-11-13 Vacuna contra vhc.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA05005203A MXPA05005203A (es) 2002-11-15 2003-11-13 Vacuna contra vhc.

Country Status (21)

Country Link
US (4) US20060135451A1 (es)
EP (2) EP1560844A1 (es)
JP (2) JP2006518331A (es)
KR (2) KR20050085010A (es)
CN (2) CN1738833A (es)
AR (1) AR041964A1 (es)
AU (2) AU2003288084A1 (es)
BR (2) BR0316244A (es)
CA (2) CA2504654A1 (es)
CO (1) CO5700833A2 (es)
GB (1) GB0226722D0 (es)
IS (2) IS7830A (es)
MA (2) MA27700A1 (es)
MX (2) MXPA05005202A (es)
NO (2) NO20052149L (es)
NZ (2) NZ539998A (es)
PL (2) PL376882A1 (es)
RU (2) RU2363492C2 (es)
TW (1) TW200502246A (es)
WO (2) WO2004046175A1 (es)
ZA (2) ZA200503802B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
CA2645177A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
AU2009273949A1 (en) * 2008-07-24 2010-01-28 Aduro Biotech Compositions and methods for the treatment of hepatitis C
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
AU2014221143B2 (en) * 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0789563B8 (en) * 1994-10-05 2004-11-17 Apollon, Inc. Hepatitis virus b and c vaccines
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
EP1232267B1 (en) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2363492C2 (ru) 2009-08-10
US20060246090A1 (en) 2006-11-02
MXPA05005203A (es) 2006-01-27
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
CN1738833A (zh) 2006-02-22
EP1560845A1 (en) 2005-08-10
CA2504715A1 (en) 2004-06-03
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
GB0226722D0 (en) 2002-12-24
WO2004046176A1 (en) 2004-06-03
AU2003288084A1 (en) 2004-06-15
NO20052136L (no) 2005-07-11
NO20052149D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
CN1738834A (zh) 2006-02-22
EP1560844A1 (en) 2005-08-10
KR20050085009A (ko) 2005-08-29
BR0316291A (pt) 2005-10-11
KR20050085010A (ko) 2005-08-29
NZ539999A (en) 2008-03-28
JP2006518331A (ja) 2006-08-10
MA27699A1 (fr) 2006-01-02
CO5700833A2 (es) 2006-11-30
CA2504654A1 (en) 2004-06-03
PL376967A1 (pl) 2006-01-23
US20090232847A1 (en) 2009-09-17
NZ539998A (en) 2008-04-30
RU2005113692A (ru) 2006-01-27
MA27700A1 (fr) 2006-01-02
AR041964A1 (es) 2005-06-01
ZA200503802B (en) 2006-08-30
PL376882A1 (pl) 2006-01-09
TW200502246A (en) 2005-01-16
AU2003288072A1 (en) 2004-06-15
IS7830A (is) 2005-04-28
IS7831A (is) 2005-04-28
WO2004046175A1 (en) 2004-06-03
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
NO20052149L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
MXPA05005202A (es) Vacuna.
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
WO2002086100A3 (en) Expression of core-glycosylated hcv envelope proteins in yeast
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
DE602004028029D1 (en) Rwendung
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
DK1290160T3 (da) Humane Pellino-polypeptider
ZA200806551B (en) Hepatitis C virus non structural fusion protein
CY1109206T1 (el) gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
WO2005002511A3 (en) Recombinant antibodies and compositions and methods for making and using the same
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
WO2004082596A3 (en) Yersinia species compositions
WO2005056051A3 (en) Hepatitis b vaccines and compositions
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
HUP0200832A2 (hu) Babesia canis oltóanyag
SE0002498D0 (sv) Papillomavirus vaccine

Legal Events

Date Code Title Description
FG Grant or registration